Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. The stock recently ...

Eli Lilly & Co.’s stock has reached new highs in recent days, becoming the first pharmaceutical company to hit a $1 trillion valuation. The surge has also lifted the founding family’s private ...

A fresh call from Bernstein has Wall Street doing a double-take. Bernstein just reset Eli Lilly’s price target. Analyst Breen cites talks about GLP-1 catalysts, robust U.S. policy, and promising ...

Philadelphia is about to become the host of the fifth Lilly Gateway Labs, a biotech incubator for early-stage companies backed by Eli Lilly & Co., writes Harold Brubaker for The Philadelphia Inquirer.

LillyDirect is a legitimate, direct-to-consumer platform that offers authentic Eli Lilly medication. This platform accepts insurance and offers self-pay options. LillyDirect is partnered with licensed ...

Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them just a few years in. Eli Lilly is rewriting the rules of pharma. Not only did ...

Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ...

Whether repurposing a song by The Beatles or leveraging the starpower of Academy Award-winner Julianne Moore, Eli Lilly has amplified several ad campaigns focused on Alzheimer’s disease and brain ...

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. The latest high-profile crossovers—which include a starry TV partnership and the ...

Pharmaceutical company Eli Lilly is looking to roll out a daily weight loss pill for patients with obesity and type 2 diabetes. A recent trial showed the drug enabled people with both conditions to ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...